Key facts
- This page summarizes Martha Morrell's Form 4 filing for NeuroPace Inc (NPCE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 25 Feb 2025, 18:52.
Martha Morrell - 21 Feb 2025 Form 4 Insider Report for NeuroPace Inc (NPCE)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- NPCE
- Reported as of
- 21 Feb 2025
- Net transaction value
- -$1,074,844
- SEC form
- 4
- Accepted by SEC
- 25 Feb 2025, 18:52:20 UTC
- Prior SEC filing
- 31 Jan 2025
- Next SEC filing
- 03 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leah Akin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Martha Morrell filed Form 4 for NeuroPace Inc (NPCE) on 25 Feb 2025.
Change
- Previous filing in this sequence was filed on 31 Jan 2025.
- Current net transaction value: -$1,074,844.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NPCE
transaction
Common Stock
Sale
- Transaction value
- $1,074,844
- Shares
- -78,334
- Change %
- -49%
- Price
- $13.72
- Shares after
- 81,993
- Date
- 21 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $14.21, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form.